Carasent Q1-26: Core strength and surface noise
The headline missed the target, but the core engine is still strong. Organic growth in the Nordics is accelerating while Germany and AI move into the “paying customer” phase. Valuation updated!
Heading into this report, I had three main items on my checklist, beyond tracking ARR, NRR etc. It was 1) the successful wrap-up of the Volvat migration, 2) the transition of the German Webcur platform from pilot to revenue, and 3) a pulse check on the new Medsum AI rollout.
Operationally, Carasent checked these boxes. Volvat is wrapped-up and live, the first paying customers are on the books in Germany, and Medsum adoption has accelerated sharply following the switch to OpenAI.
However, the stock price tells a different story. Carasent’s shares fell following the release, dropping from SEK 24+ to SEK 22.90. The reaction was triggered by a “miss” on total revenue growth, which came in at just 6%. To the casual observer, it looks like a slowdown. To those of us looking at the unit economics, it was a quarter of continued de-risking obscured by one-off noise.
In this update, I break down why the market is misinterpreting the consulting revenue drop and why the core subscription business is actually healthier than it was three months ago.
